Skip to main content
. 2022 Jun 22;158(8):893–899. doi: 10.1001/jamadermatol.2022.2149

Figure 2. Frequency of CD19+ Blood B Cells, Serum Concentration of Rituximab (RTX), and Anti–Desmoglein 3 Antibody (DSG3 Ab) Serum Level in Patients With and Without Antirituximab Antibodies (ARAs).

Figure 2.

A, CD19+ B cells in the blood of patients with or without ARAs from month 12 (time of B-cell reconstitution) to month 18 (6 months after the first maintenance infusion of RTX at month 12). B, Serum concentration of RTX at month 14 (2 months after the first maintenance infusion of RTX at month 12) in patients without and with ARAs. C, Anti-DSG3 Ab serum level at month 18 in patients without and with ARAs. Relapsing patients are identified in orange. The positivity threshold of anti-DSG3 Abs is represented by the dotted line at 20 AU/mL.

aP < .001.

bP < .05.